评价灯盏细辛注射液佐治冠心病心绞痛的疗效及安全性。计算机检索Cochrane图书馆，Medline，EMbase，CBM，CNKI，VIP和万方数据库中关于灯盏细辛注射液联合西医常规对冠心病心绞痛治疗的随机对照试验。根据CochraneReviewer′sHandbook5.1评价标准和工具评价纳入文献质量，用RevMan5.2软件进行Meta分析。该研究共纳入30个随机对照试验，总样本数为3086例，试验组1572例和对照组1514例。Meta分析结果显示，灯盏细辛注射液佐治冠心病心绞痛与西医常规治疗相比能够减少心血管事件的发生（OR=0.33;95%CI：[0.16，0.67];P=0.002）;灯盏细辛注射液佐治冠心病心绞痛有效率（OR=3.97;95%CI：[3.15，5.02];P<0.00001）和心电图疗效（OR=2.21;95%CI：[1.83，2.68];P<0.00001）优于西医常规治疗。漏斗图有一定的不对称，预示可能存在发表偏倚。现有证据表明，灯盏细辛注射液联合常规疗法治疗冠心病心绞痛在临床疗效及心电图改善等方面比单用西医常规疗效较好。但基于研究的局限，所获得的支持证据强度有待提升，且需设计严谨、随访时间更长的临床研究加以证实。
[关键词]灯盏细辛注射液;冠心病心绞痛;随机对照试验;系统综述;Meta分析
DengzhanXixininjectionasanadjuvanttreatmentforanginapectoris：
asystematicreviewandMeta-analysisofrandomizedcontrolledtrials
WANGFeng-jiao1，2，XIEYan-ming1，LIAOXing1，3*，JIAMin4
（1.InstituteofBasicResearchinClinicalMedicine，ChinaAcademyofChineseMedicalSciences，Beijing100700，China;
2.TheThirdAffiliatedHospitalofBeijingUniversityofChineseMedicine，Beijing100029，China;
3.PostdoctoralresearchstationofChinaAcademyofChineseMedicalSciences，Beijing100700，China;
4.XiyuanHospital，ChinaAcademyofChineseMedicalSciences，Beijing100091，China）
[Abstract]ThepaperistosystematicallyevaluatetheefficacyandsafetyofDengZhanXiXininjection（DZXXI）asanadjuvanttreatmentforpatientswithanginapectoris.TheCochraneLibrary，Medline，EMbase，CBM，CNKI，VIP，andWanfangDatabaseweresearched.Randomizedcontrolledtrials（RCTs）ofDZXXIcombinedwithwesternmedicineroutinetreatmentversuswesternmedicineroutinetreatmentaloneforanginapectorispatientswereallincluded.AlltrialswereassessedaccordingtotheCochraneReviewer′sHandbook5.1forSystematicReviewsofInterventionandMetaanalyseswereperformedbyRevMan5.2Software.Atotalof30RCTs（3086patientsincluding1572patientsoftreatmentgroupand1514patientsofcontrolgroup）wereincluded.Meta-analysisoftreatmentgroupcomparedwithcontrolgroupshowedsuperioreffectoverreducingcardiovascularevents（OR=0.33;95%CI：[0.16，0.67]，P=0.002），improvingeffectiverateofDZXXIasadjuvanttreatmentforanginapectorispatients（OR=3.97;95%CI：[3.15，5.02];P<0.00001）andelectrocardiogramcurativeeffect（OR=2.21;95%CI：[1.83，2.68];P<0.00001）.Funnelfigureseemedthattherewaspublicationbias.Thecurrentlimitedevidenceshowedthatwhencomparedwiththecontrolgroup，treatmentgroupwassuperiorinimprovingpatientswithanginapectoris.Butbasedonthelimitationsofthestudy，rigorousdesignwithlongfollowupclinicaltrialsarenecessaryforfurtherevidence.
[Keywords]DengzhanXixininjection;anginapectoris;randomizedcontrolledtrial;systematicreview;Meta-analysis